Systematic evaluation of efficacy and safety of anlotinib in the treatment of osteosarcoma
YU Weize
ZHANG Yuan
Abstract：Objective To conduct a systematic evaluation of the efficacy and safety of anlotinib in the treatment of osteosarcoma(OS),aiming to provide a foundation for its clinical application in OS therapy.Methods In this study,we systematically searched multiple databases,including CNKI,Wanfang,VIP,SinoMed,PubMed,Embase,the Cochrane Library,and Web of Science,to gather relevant studies on the application of anlotinib in the treatment of OS.Our search encompassed the entire period from the establishment of these databases up to May 22,2024,ensuring a comprehensive re-view of existing literature.We extracted literature data,focusing on key metrics such as progression-free survival(PFS),disease control rate(DCR),overall response rate(ORR),and the occurrence of adverse events(AEs).Additionally,we analyzes the sensitivity and risk of bias of the included studies utilizing Stata 18 software.Results A total of 10 studies were included,involving 194 OS patients.Meta-analysis results indicated that among 194 cases,the PFS of OS patients was 4.96 months(95%CI:3.79-6.13,P=0.58),the DCR was 69%(95%CI:0.51-0.85,P<0.01),while the ORR was 11%(95%CI:0.06-0.16,P<0.01).Subgroup analysis results indicated that in the anlotinib monotherapy group,the PFS was 5.03 months(95%CI:3.66-6.39,P=0.39),the DCR was 59%(95%CI:0.39-0.77,P=0.04),and the ORR was 5%(95%CI:0.01-0.12,P<0.01).In contrast,in the anlotinib combined with chemotherapy group,the PFS was 4.93 months(95%CI:2.23-7.62,P=0.85),the DCR was 80%(95%CI:0.58-0.96,P=0.01),and the ORR was 19%(95%CI:0.10-0.55,P<0.01).The AEs included hand-foot syndrome at 21%(95%CI:0.01-0.51),hyper-tension at 22%(95%CI:0.02-0.53),and fatigue at 23%(95%CI:0.01-0.55),among others.The most prevalent Grade≥Ⅲ adverse event was neutropenia,observed in 11%of patients(95%CI:0.00-0.34).This study exhibited a high sensitivity and a low likelihood of publication bias.Conclusion Anlotinib demonstrates favorable efficacy and high safety in the treatment of OS.
Keywords：anlotinibosteosarcomaeffectivenesssafetyMeta-analysis
Publication Date：2025-05-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 12-17 )